SCHEMBL2425571

SCHEMBL2425571

OC(c1cccnc1)C1CCOCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.46
FPR2 P25090 1/20 0.41
KCNA5 P22460 2/20 0.41
CFTR P13569 1/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A4 P31645 1/20 0.41
SLC6A3 Q01959 1/20 0.41
GOPC Q9HD26 1/20 0.41
TSHR P16473 2/20 0.40
GAA P10253 1/20 0.40
CYP17A1 P05093 1/20 0.40
HSD17B10 Q99714 2/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
DGAT1 O75907 1/20 0.39
LMNA P02545 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
KCNH2 Q12809 1/20 0.38
KDM4A O75164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30896272 0.88 SMN1; SMN2 (0.53) SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3
SCHEMBL8795521 0.88 SMN1; SMN2 (0.53) SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3
SCHEMBL5378828 0.85 SLC6A4 (0.42) SMN1; SMN2FPR2KCNA5CFTRSLC6A2
SCHEMBL8601458 0.81 SLC6A4 (0.53) SMN1; SMN2SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL8602800 0.81 SLC6A4 (0.53) SMN1; SMN2SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL8603837 0.81 SLC6A4 (0.53) SMN1; SMN2SLC6A2SLC6A4SLC6A3KCNH2
Hydrochloric Acid SCHEMBL25255123 0.79 SLC6A4 (0.52) SMN1; SMN2SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL17840999 0.79 KDM4E (0.49) TSHRKDM4EL3MBTL1HRH3KDM4A
SCHEMBL15995417 0.79 KDM4E (0.49) TSHRKDM4EL3MBTL1HRH3KDM4A
SCHEMBL16861726 0.79 KDM4E (0.49) TSHRKDM4EL3MBTL1HRH3KDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2374802-B1 KYNURENINE PRODUCTION INHIBITOR KYOWA HAKKO KIRIN CO LTD (JP) 2014-04-23 EP disclosed
US-8673908-B2 Kynurenine production inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-03-18 US disclosed
EP-2374802-A1 KYNURENINE PRODUCTION INHIBITOR Kyowa Hakko Kirin Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110237584-A1 KYNURENINE PRODUCTION INHIBITOR KYOWA KIRIN CO., LTD. (JP) 2011-09-29 US disclosed
US-20110237584-A1 KYNURENINE PRODUCTION INHIBITOR KYOWA KIRIN CO., LTD. (JP) 2011-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237584-A1 KYNURENINE PRODUCTION INHIBITOR KYNU, KMO, IDO1 SMN1; SMN2 4398/4885FPR2 264/4885KCNA5 1343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.